Identification

Name
Oxycodone
Accession Number
DB00497  (APRD00387)
Type
Small Molecule
Groups
Approved, Illicit, Investigational
Description

Oxycodone is a semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. An extended-release (ER) form of oxycodone (Xtampza ER) was approved for the management of daily, around-the-clock pain management in April, 2016.

Structure
Thumb
Synonyms
  • (-)-14-Hydroxydihydrocodeinone
  • 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • 4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • Dihydro-14-hydroxycodeinone
  • Dihydrohydroxycodeinone
  • Dihydroxycodeinone
  • Oxicodona
  • Oxycodone
  • Oxycodonum
External IDs
IDS-NO-002 / N02AA05 / NSC-19043 / PF-00345439 / PTI-821
Product Ingredients
IngredientUNIICASInChI Key
Oxycodone hydrochlorideC1ENJ2TE6C124-90-3MUZQPDBAOYKNLO-RKXJKUSZSA-N
Oxycodone terephthalateM04XWV43UF124133-68-2BTEYIHUKHHAVAN-KDKWOIFOSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Oxycodone CRTablet, extended release20 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release80 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release10 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release40 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release5 mgOralActavis Pharma Company2012-11-26Not applicableCanada
OxaydoTablet5 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2015-09-01Not applicableUs
OxaydoTablet7.5 mg/1OralEgalet Ltd2015-09-01Not applicableUs
OxaydoTablet5 mg/1OralEgalet Ltd2015-09-01Not applicableUs
OxaydoTablet7.5 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2015-09-01Not applicableUs
OxectaTablet7.5 mg/1OralPfizer Laboratories Div Pfizer Inc.2011-06-17Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxycodone CRTablet, extended release40 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release5.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release80.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release60 mgOralApotex Corporation2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended release30 mgOralApotex Corporation2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended release20.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release15 mgOralApotex Corporation2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended release10.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Oxycodone HClTablet30 mg/1OralDirectrx2016-02-22Not applicableUs
Oxycodone HCLTablet15 mg/1OralDirectrx2016-02-08Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-oxycodone/acetOxycodone hydrochloride (5 mg) + Acetaminophen (325 mg)TabletOralApotex Corporation2009-04-15Not applicableCanada
EndocetOxycodone hydrochloride (5 mg) + Acetaminophen (325 mg)TabletOralBristol Myers Squibb1995-12-31Not applicableCanada
EndocetOxycodone hydrochloride (2.5 mg/1) + Acetaminophen (325 mg/1)TabletOralPar Pharmaceutical2003-03-06Not applicableUs
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (325 mg/1)TabletOralLake Erie Medical Dba Quality Care Produts Llc2003-03-062018-03-15Us
EndocetOxycodone hydrochloride (7.5 mg/1) + Acetaminophen (500 mg/1)TabletOralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-022017-02-03Us
EndocetOxycodone hydrochloride (7.5 mg/1) + Acetaminophen (325 mg/1)TabletOralPar Pharmaceutical2003-03-06Not applicableUs
EndocetOxycodone hydrochloride (5 mg/1) + Acetaminophen (325 mg/1)TabletOralLake Erie Medical Dba Quality Care Produts Llc2000-05-262018-03-15Us
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (325 mg/1)TabletOralPar Pharmaceutical2003-03-06Not applicableUs
EndocetOxycodone hydrochloride (5 mg/1) + Acetaminophen (325 mg/1)TabletOralPar Pharmaceutical2000-05-26Not applicableUs
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (325 mg/1)TabletOralStat Rx USA2003-03-062018-02-08Us
International/Other Brands
Oxanest / OxyIR
Categories
UNII
CD35PMG570
CAS number
76-42-6
Weight
Average: 315.3636
Monoisotopic: 315.147058165
Chemical Formula
C18H21NO4
InChI Key
BRUQQQPBMZOVGD-XFKAJCMBSA-N
InChI
InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
IUPAC Name
(1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O

Pharmacology

Indication

For the treatment of diarrhoea, pulmonary oedema and for the relief of moderate to moderately severe pain.

Associated Conditions
Pharmacodynamics

Oxycodone, a semisynthetic opiate agonist derived from the opioid alkaloid, thebaine, is similar to other phenanthrene derivatives such as hydrocodone and morphine. Oxycodone is available in combination with aspirin or acetaminophen to control pain and restless leg and Tourette syndromes.

Mechanism of action

Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
AKappa-type opioid receptor
agonist
Human
ADelta-type opioid receptor
agonist
Human
UKappa-type opioid receptor 2b
agonist
Human
Ualpha1-acid glycoprotein
binder
Human
Absorption

Well absorbed with an oral bioavailability of 60% to 87%

Volume of distribution
  • 2.6 L/kg
Protein binding

45%

Metabolism

Hepatic

Route of elimination

Oxycodone and its metabolites are excreted primarily via the kidney.

Half life

4.5 hours

Clearance
  • 0.8 L/min [adults]
Toxicity

Symptoms of overdose include respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Oxycodone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe risk or severity of adverse effects can be increased when (2-benzhydryloxyethyl)diethyl-methylammonium iodide is combined with Oxycodone.Experimental
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Oxycodone.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Oxycodone.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Oxycodone.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Oxycodone.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Oxycodone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbirateroneThe serum concentration of Oxycodone can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of hypotension and central nervous system depression can be increased when Acepromazine is combined with Oxycodone.Approved, Vet Approved
AceprometazineThe risk or severity of hypotension and central nervous system depression can be increased when Aceprometazine is combined with Oxycodone.Approved
AcetazolamideThe therapeutic efficacy of Acetazolamide can be decreased when used in combination with Oxycodone.Approved, Vet Approved
AcetophenazineThe risk or severity of hypotension and central nervous system depression can be increased when Acetophenazine is combined with Oxycodone.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Acetylglycinamide chloral hydrate.Experimental
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Oxycodone.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Adipiplon.Investigational
AgmatineThe risk or severity of adverse effects can be increased when Agmatine is combined with Oxycodone.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alfentanil.Approved, Illicit
AlimemazineThe risk or severity of hypotension and central nervous system depression can be increased when Alimemazine is combined with Oxycodone.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Oxycodone.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxycodone.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alverine.Approved, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alvimopan.Approved, Investigational
AmantadineThe risk or severity of adverse effects can be increased when Amantadine is combined with Oxycodone.Approved
AmikacinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideThe therapeutic efficacy of Amiloride can be decreased when used in combination with Oxycodone.Approved
AmineptineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Oxycodone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Oxycodone.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amitriptylinoxide.Approved, Investigational
Ammonium chlorideAmmonium chloride may increase the excretion rate of Oxycodone which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Oxycodone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
AmprenavirThe risk or severity of adverse effects can be increased when Amprenavir is combined with Oxycodone.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aniracetam.Experimental
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Oxycodone.Approved
ApalutamideThe serum concentration of Oxycodone can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Oxycodone is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Apramycin.Experimental, Vet Approved
AprepitantThe risk or severity of adverse effects can be increased when Aprepitant is combined with Oxycodone.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aripiprazole lauroxil.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Asenapine.Approved
AsunaprevirThe metabolism of Oxycodone can be decreased when combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Oxycodone.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Oxycodone.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Azaperone.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when Oxycodone is combined with AZD-3043.Investigational
AzelastineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Oxycodone.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Oxycodone is combined with Baclofen.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Barbital.Illicit
Barbituric acid derivativeThe risk or severity of adverse effects can be increased when Barbituric acid derivative is combined with Oxycodone.Experimental, Illicit
BeclamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benactyzine.Withdrawn
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxycodone.Approved
BenmoxinBenmoxin may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxycodone.Approved
BenziloneThe risk or severity of adverse effects can be increased when Benzilone is combined with Oxycodone.Experimental
BenzoctamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benzoctamine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit
BenzquinamideThe risk or severity of adverse effects can be increased when Benzquinamide is combined with Oxycodone.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Oxycodone.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benzyl alcohol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Oxycodone.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bezitramide.Experimental, Illicit, Withdrawn
BifemelaneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bifeprunox.Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxycodone.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Oxycodone.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Oxycodone.Approved
BL-1020The risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Oxycodone.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Blonanserin.Approved, Investigational
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Oxycodone.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Oxycodone.Experimental
BosentanThe serum concentration of Oxycodone can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Oxycodone is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Oxycodone is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
BrinzolamideThe therapeutic efficacy of Brinzolamide can be decreased when used in combination with Oxycodone.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromocriptine.Approved, Investigational
BromotheophyllineThe therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Oxycodone.Approved
BromperidolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brotizolam.Approved, Investigational, Withdrawn
BuclizineThe risk or severity of adverse effects can be increased when Buclizine is combined with Oxycodone.Approved
BufotenineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bufotenine.Experimental, Illicit
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Oxycodone.Approved
BuprenorphineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Oxycodone.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxycodone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxycodone.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butalbital.Approved, Illicit
ButaperazineThe risk or severity of hypotension and central nervous system depression can be increased when Butaperazine is combined with Oxycodone.Experimental
ButethalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butorphanol.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butriptyline.Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Oxycodone.Approved, Investigational, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cabergoline.Approved
CamazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Camazepam.Approved, Illicit
CamylofinThe risk or severity of adverse effects can be increased when Camylofin is combined with Oxycodone.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Oxycodone.Approved
CannabidiolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cannabidivarin.Investigational
Canrenoic acidThe therapeutic efficacy of Canrenoic acid can be decreased when used in combination with Oxycodone.Approved, Withdrawn
CanrenoneThe therapeutic efficacy of Canrenone can be decreased when used in combination with Oxycodone.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Oxycodone is combined with Captodiame.Approved, Investigational
CarbamazepineThe metabolism of Oxycodone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carbinoxamine.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Oxycodone.Approved, Investigational
CarbromalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carisoprodol.Approved
CaroxazoneCaroxazone may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Withdrawn
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Oxycodone.Approved, Investigational, Nutraceutical, Vet Approved
CathinoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cathinone.Illicit
CeritinibThe risk or severity of adverse effects can be increased when Ceritinib is combined with Oxycodone.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxycodone.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Oxycodone.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxycodone.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Oxycodone.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Oxycodone.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Oxycodone.Illicit, Withdrawn
ChlorproethazineThe risk or severity of hypotension and central nervous system depression can be increased when Chlorproethazine is combined with Oxycodone.Experimental
ChlorpromazineThe risk or severity of hypotension and central nervous system depression can be increased when Chlorpromazine is combined with Oxycodone.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxycodone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Oxycodone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe therapeutic efficacy of Cicletanine can be decreased when used in combination with Oxycodone.Investigational
CilansetronThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cilansetron.Investigational
CimetidineThe metabolism of Oxycodone can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Oxycodone can be decreased when combined with Cinacalcet.Approved
CinitaprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cinolazepam.Approved
CisaprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Oxycodone.Approved
ClarithromycinThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Oxycodone.Approved
ClemastineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clobazam.Approved, Illicit
ClofenamideThe therapeutic efficacy of Clofenamide can be decreased when used in combination with Oxycodone.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Oxycodone.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clonidine.Approved
ClopamideThe therapeutic efficacy of Clopamide can be decreased when used in combination with Oxycodone.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clorazepate.Approved, Illicit
ClorexoloneThe therapeutic efficacy of Clorexolone can be decreased when used in combination with Oxycodone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Oxycodone.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Oxycodone.Approved
CobicistatThe risk or severity of adverse effects can be increased when Cobicistat is combined with Oxycodone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Oxycodone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Codeine.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Colistin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Oxycodone.Approved, Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Crizotinib is combined with Oxycodone.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Oxycodone.Approved, Investigational
CyamemazineThe risk or severity of hypotension and central nervous system depression can be increased when Cyamemazine is combined with Oxycodone.Approved
CyclizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Oxycodone.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxycodone.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Oxycodone.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Oxycodone.Approved
CycrimineThe risk or severity of adverse effects can be increased when Cycrimine is combined with Oxycodone.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Oxycodone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe risk or severity of adverse effects can be increased when Danazol is combined with Oxycodone.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Oxycodone.Approved, Investigational, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dantrolene.Approved, Investigational
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Oxycodone.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Oxycodone.Approved, Investigational
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Oxycodone.Approved
DasatinibThe serum concentration of Oxycodone can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Oxycodone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe risk or severity of adverse effects can be increased when Delavirdine is combined with Oxycodone.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Oxycodone.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of hyponatremia can be increased when Oxycodone is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Oxycodone.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Oxycodone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxycodone.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dextofisopam.Investigational
DextroamphetamineDextroamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Oxycodone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dichloralphenazone.Approved, Illicit
DiclofenamideThe therapeutic efficacy of Diclofenamide can be decreased when used in combination with Oxycodone.Approved, Investigational
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxycodone.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Oxycodone.Approved, Illicit
DifemerineThe risk or severity of adverse effects can be increased when Difemerine is combined with Oxycodone.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Difenoxin.Approved, Illicit
DihexyverineThe risk or severity of adverse effects can be increased when Dihexyverine is combined with Oxycodone.Experimental
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Oxycodone.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dimethyltryptamine.Experimental, Illicit
DimetindeneThe risk or severity of adverse effects can be increased when Dimetindene is combined with Oxycodone.Approved, Investigational
DiphemanilThe risk or severity of adverse effects can be increased when Diphemanil is combined with Oxycodone.Experimental
Diphemanil MethylsulfateThe risk or severity of adverse effects can be increased when Diphemanil Methylsulfate is combined with Oxycodone.Approved, Vet Approved, Withdrawn
DiphenhydramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diphenhydramine.Approved, Investigational
DiphenidolThe risk or severity of adverse effects can be increased when Diphenidol is combined with Oxycodone.Approved, Investigational, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diphenoxylate.Approved, Illicit
DisopyramideThe risk or severity of adverse effects can be increased when Disopyramide is combined with Oxycodone.Approved
DixyrazineThe risk or severity of hypotension and central nervous system depression can be increased when Dixyrazine is combined with Oxycodone.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Oxycodone.Approved
DolasetronThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Oxycodone is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Doramectin.Vet Approved
DorzolamideThe therapeutic efficacy of Dorzolamide can be decreased when used in combination with Oxycodone.Approved
DosulepinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Doxacurium.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Oxycodone.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Oxycodone.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Oxycodone is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit
DronedaroneThe risk or severity of adverse effects can be increased when Dronedarone is combined with Oxycodone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Oxycodone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Oxycodone.Approved
DyclonineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dyclonine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Edivoxetine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Oxycodone.Approved, Investigational
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Oxycodone.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Oxycodone.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eltoprazine.Investigational
EluxadolineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Emepronium.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Oxycodone.Approved
EmylcamateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Oxycodone can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Epinastine.Approved, Investigational
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Oxycodone.Experimental
EplerenoneThe therapeutic efficacy of Eplerenone can be decreased when used in combination with Oxycodone.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ergotamine.Approved
ErythromycinThe risk or severity of adverse effects can be increased when Erythromycin is combined with Oxycodone.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Oxycodone.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Esmirtazapine.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxycodone.Approved, Investigational
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxycodone.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Oxycodone.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethadione.Experimental
EthanolOxycodone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Oxycodone.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethotoin.Approved
EthoxzolamideThe therapeutic efficacy of Ethoxzolamide can be decreased when used in combination with Oxycodone.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Oxycodone can be decreased when it is combined with Etravirine.Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Oxycodone.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ezogabine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenpiveriniumThe risk or severity of adverse effects can be increased when Fenpiverinium is combined with Oxycodone.Experimental
FenquizoneThe therapeutic efficacy of Fenquizone can be decreased when used in combination with Oxycodone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fenyramidol.Experimental
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxycodone.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fexofenadine.Approved, Investigational
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Oxycodone.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluanisone.Experimental
FluconazoleThe risk or severity of adverse effects can be increased when Fluconazole is combined with Oxycodone.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Oxycodone.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of hypotension and central nervous system depression can be increased when Fluphenazine is combined with Oxycodone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flurazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluticasone propionate.Approved
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Oxycodone.Approved
FosaprepitantThe serum concentration of Oxycodone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Oxycodone can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Oxycodone.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational, Vet Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Oxycodone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Oxycodone can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gaboxadol.Investigational
GallamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gedocarnil.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Oxycodone is combined with GENTAMICIN C1A.Experimental
GepefrineGepefrine may increase the analgesic activities of Oxycodone.Experimental
GepironeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Glutethimide.Approved, Illicit
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Oxycodone.Approved, Investigational
Glycerol PhenylbutyrateThe metabolism of Oxycodone can be decreased when combined with Glycerol Phenylbutyrate.Approved
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Oxycodone.Approved, Investigational, Vet Approved
GranisetronThe risk or severity of adverse effects can be increased when Granisetron is combined with Oxycodone.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hexobarbital.Approved
HexocycliumThe risk or severity of adverse effects can be increased when Hexocyclium is combined with Oxycodone.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxycodone.Approved
Homatropine MethylbromideThe risk or severity of adverse effects can be increased when Homatropine Methylbromide is combined with Oxycodone.Approved
HydracarbazineHydracarbazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Experimental
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxycodone.Approved, Vet Approved
HydrocodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxycodone.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Oxycodone.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hygromycin B.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxycodone.Approved
HypericinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hypericin.Investigational
IbopamineThe therapeutic efficacy of Ibopamine can be decreased when used in combination with Oxycodone.Experimental
IdalopirdineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Idalopirdine.Investigational
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Oxycodone.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Imagabalin.Investigational
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Oxycodone.Approved
ImidafenacinThe risk or severity of adverse effects can be increased when Imidafenacin is combined with Oxycodone.Approved, Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Oxycodone.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Imipramine oxide.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Indalpine.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxycodone.Approved
IndinavirThe risk or severity of adverse effects can be increased when Indinavir is combined with Oxycodone.Approved
IndiplonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Oxycodone.Approved
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium is combined with Oxycodone.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Iproclozide.Withdrawn
IproniazidIproniazid may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Withdrawn
IsavuconazoleThe risk or severity of adverse effects can be increased when Isavuconazole is combined with Oxycodone.Approved, Investigational
IsavuconazoniumThe risk or severity of adverse effects can be increased when Isavuconazonium is combined with Oxycodone.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Isepamicin.Experimental
IsocarboxazidIsocarboxazid may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe risk or severity of adverse effects can be increased when Isoniazid is combined with Oxycodone.Approved, Investigational
IsopropamideThe risk or severity of adverse effects can be increased when Isopropamide is combined with Oxycodone.Approved, Vet Approved
IsosorbideThe therapeutic efficacy of Isosorbide can be decreased when used in combination with Oxycodone.Approved, Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Oxycodone.Approved, Investigational
IvacaftorThe serum concentration of Oxycodone can be increased when it is combined with Ivacaftor.Approved
KanamycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketamine.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Oxycodone.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Oxycodone.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lacosamide.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Oxycodone.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Oxycodone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lamotrigine.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxycodone.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Oxycodone.Approved
LincomycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lincomycin.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Oxycodone.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lithium cation.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Oxycodone can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Oxycodone.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxycodone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Oxycodone can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lortalamine.Experimental
LovastatinThe risk or severity of adverse effects can be increased when Lovastatin is combined with Oxycodone.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxycodone.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxycodone.Approved, Investigational
LuliconazoleThe risk or severity of adverse effects can be increased when Luliconazole is combined with Oxycodone.Approved
LumacaftorThe metabolism of Oxycodone can be increased when combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lumateperone.Investigational
LumefantrineThe metabolism of Oxycodone can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lurasidone.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Oxycodone.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Oxycodone can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium Trisilicate.Approved
ManidipineThe metabolism of Oxycodone can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Oxycodone.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Oxycodone.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Oxycodone.Experimental
MazindolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mazindol.Approved, Investigational
MebanazineMebanazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Withdrawn
MebeverineThe risk or severity of adverse effects can be increased when Mebeverine is combined with Oxycodone.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mebutamate.Approved
MebutizideThe therapeutic efficacy of Mebutizide can be decreased when used in combination with Oxycodone.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Medifoxamine.Experimental
MefrusideThe therapeutic efficacy of Mefruside can be decreased when used in combination with Oxycodone.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Oxycodone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Oxycodone is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Melperone.Approved, Investigational
MepenzolateThe risk or severity of adverse effects can be increased when Mepenzolate is combined with Oxycodone.Approved
MephedroneMephedrone may increase the analgesic activities of Oxycodone.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mephenoxalone.Experimental
MephentermineMephentermine may increase the analgesic activities of Oxycodone.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxycodone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Meptazinol.Experimental
MersalylThe therapeutic efficacy of Mersalyl can be decreased when used in combination with Oxycodone.Approved
MesoridazineThe risk or severity of hypotension and central nervous system depression can be increased when Mesoridazine is combined with Oxycodone.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Oxycodone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxycodone.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metharbital.Withdrawn
MethazolamideThe therapeutic efficacy of Methazolamide can be decreased when used in combination with Oxycodone.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxycodone.Approved
MethotrimeprazineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Oxycodone.Experimental
MethscopolamineThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Oxycodone.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methsuximide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxycodone.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Oxycodone.Approved
Methylene blueMethylene blue may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Oxycodone.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methysergide.Approved
MeticraneThe therapeutic efficacy of Meticrane can be decreased when used in combination with Oxycodone.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Oxycodone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metoclopramide.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metocurine Iodide.Approved, Withdrawn
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxycodone.Approved
MetyrosineOxycodone may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mianserin.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Mibefradil is combined with Oxycodone.Investigational, Withdrawn
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Oxycodone.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Midazolam.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Oxycodone.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Oxycodone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Oxycodone is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Oxycodone.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational
MirabegronThe metabolism of Oxycodone can be decreased when combined with Mirabegron.Approved
MirtazapineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Oxycodone can be decreased when it is combined with Mitotane.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Oxycodone is combined with MK-212.Investigational
MMDAMMDA may increase the analgesic activities of Oxycodone.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational
ModafinilThe serum concentration of Oxycodone can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Moperone.Experimental
MoricizineThe risk or severity of hypotension and central nervous system depression can be increased when Moricizine is combined with Oxycodone.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when Oxycodone is combined with MRK-409.Experimental
MuzolimineThe therapeutic efficacy of Muzolimine can be decreased when used in combination with Oxycodone.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational
NafcillinThe serum concentration of Oxycodone can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Oxycodone is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nalbuphine.Approved
NaloxoneThe risk or severity of adverse effects can be increased when Naloxone is combined with Oxycodone.Approved, Vet Approved
NaltrexoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Naltrexone.Approved, Investigational, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Oxycodone is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Oxycodone.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Neamine.Experimental
NefiracetamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nefiracetam.Investigational
NelfinavirThe risk or severity of adverse effects can be increased when Nelfinavir is combined with Oxycodone.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Netilmicin.Approved, Investigational
NetupitantThe risk or severity of adverse effects can be increased when Netupitant is combined with Oxycodone.Approved, Investigational
NevirapineThe metabolism of Oxycodone can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Niaprazine.Experimental
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Oxycodone.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nicomorphine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Oxycodone.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nitrous oxide.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nordazepam.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Oxycodone.Approved
OctamoxinOctamoxin may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxycodone.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Olaparib is combined with Oxycodone.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Oxycodone.Approved
OpipramolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Opium.Approved, Illicit
OrphenadrineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Oxycodone is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Oxycodone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Oxycodone can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Oxycodone.Experimental, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxazepam.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Oxycodone.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxprenolol.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxycodone.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxypertine.Experimental
OxyphencyclimineThe risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Oxycodone.Approved
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Oxycodone.Investigational, Withdrawn
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Oxycodone.Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Oxycodone can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Paliperidone.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Oxycodone is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pancuronium.Approved
PanobinostatThe serum concentration of Oxycodone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeOxycodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Paramethadione.Approved
PargylinePargyline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Oxycodone.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Oxycodone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxycodone.Approved
PenbutololThe risk or severity of adverse effects can be increased when Oxycodone is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Penimepicycline.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Oxycodone.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxycodone.Approved, Vet Approved
PenthienateThe risk or severity of adverse effects can be increased when Penthienate is combined with Oxycodone.Experimental
PentobarbitalThe metabolism of Oxycodone can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Oxycodone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
PerazineThe risk or severity of hypotension and central nervous system depression can be increased when Perazine is combined with Oxycodone.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perospirone.Approved
PerphenazineThe risk or severity of hypotension and central nervous system depression can be increased when Perphenazine is combined with Oxycodone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxycodone.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phencyclidine.Illicit
PhenelzinePhenelzine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pheneturide.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Oxycodone.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenibut.Experimental
PheniprazinePheniprazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Withdrawn
PhenobarbitalThe metabolism of Oxycodone can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Oxycodone.Approved, Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Oxycodone.Approved, Illicit
Phenylbutyric acidThe metabolism of Oxycodone can be decreased when combined with Phenylbutyric acid.Approved, Investigational
PhenytoinThe metabolism of Oxycodone can be increased when combined with Phenytoin.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Oxycodone is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Oxycodone.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pimozide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pipecuronium.Approved
PipenzolateThe risk or severity of adverse effects can be increased when Pipenzolate is combined with Oxycodone.Experimental
PiperidolateThe risk or severity of adverse effects can be increased when Piperidolate is combined with Oxycodone.Experimental
PipotiazineThe risk or severity of hypotension and central nervous system depression can be increased when Pipotiazine is combined with Oxycodone.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxycodone.Approved
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Oxycodone.Approved
PiritramideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pirlimycin.Vet Approved
PirlindolePirlindole may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
PitolisantThe serum concentration of Oxycodone can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pivagabine.Investigational
PivhydrazinePivhydrazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pizotifen.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Oxycodone.Approved, Investigational
PlazomicinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Oxycodone.Approved, Investigational
PoldineThe risk or severity of adverse effects can be increased when Poldine is combined with Oxycodone.Experimental
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Oxycodone.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Oxycodone.Approved, Vet Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Oxycodone.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pomalidomide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Oxycodone.Approved, Investigational, Vet Approved
PotassiumThe therapeutic efficacy of Potassium can be decreased when used in combination with Oxycodone.Approved, Experimental
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Oxycodone.Approved, Investigational
Potassium cationThe therapeutic efficacy of Potassium cation can be decreased when used in combination with Oxycodone.Approved, Investigational
Potassium CitrateThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Oxycodone.Approved, Investigational, Vet Approved
PramipexoleOxycodone may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Oxycodone can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pridinol.Experimental
PrifiniumThe risk or severity of adverse effects can be increased when Prifinium is combined with Oxycodone.Experimental
PrimidoneThe metabolism of Oxycodone can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Oxycodone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxycodone.Approved
ProgabideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of hypotension and central nervous system depression can be increased when Promazine is combined with Oxycodone.Approved, Vet Approved
PromethazineThe risk or severity of hypotension and central nervous system depression can be increased when Promethazine is combined with Oxycodone.Approved, Investigational
PropafenoneThe metabolism of Oxycodone can be decreased when combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Oxycodone is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxycodone.Approved
PropericiazineThe risk or severity of hypotension and central nervous system depression can be increased when Propericiazine is combined with Oxycodone.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of hypotension and central nervous system depression can be increased when Propiopromazine is combined with Oxycodone.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Oxycodone.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Propofol.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Oxycodone is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Oxycodone.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Proxibarbal.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Oxycodone.Approved
PRX-08066The risk or severity of adverse effects can be increased when Oxycodone is combined with PRX-08066.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Oxycodone.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxycodone.Approved
QuinidineThe metabolism of Oxycodone can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Oxycodone can be increased when combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ramelteon.Approved, Investigational
RamosetronThe therapeutic efficacy of Ramosetron can be decreased when used in combination with Oxycodone.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Rapacuronium.Withdrawn
RasagilineRasagiline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Oxycodone is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxycodone.Approved, Investigational
RevefenacinThe risk or severity of adverse effects can be increased when Revefenacin is combined with Oxycodone.Investigational
RheinThe metabolism of Oxycodone can be decreased when combined with Rhein.Experimental
RibostamycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ribostamycin.Approved, Investigational
RifampicinThe serum concentration of Oxycodone can be decreased when it is combined with Rifampicin.Approved
RifamycinThe metabolism of Oxycodone can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Oxycodone can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Oxycodone can be increased when combined with Rifaximin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Riluzole.Approved, Investigational
RimexoloneThe metabolism of Oxycodone can be increased when combined with Rimexolone.Approved
RitanserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Oxycodone.Investigational
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Oxycodone.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Oxycodone.Approved
RociverineThe risk or severity of adverse effects can be increased when Rociverine is combined with Oxycodone.Experimental
RocuroniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Rocuronium.Approved
RolapitantThe metabolism of Oxycodone can be decreased when combined with Rolapitant.Approved, Investigational
RolipramThe risk or severity of adverse effects can be increased when Oxycodone is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Rolitetracycline.Approved
RolofyllineThe therapeutic efficacy of Rolofylline can be decreased when used in combination with Oxycodone.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Romifidine.Vet Approved
RopiniroleOxycodone may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineOxycodone may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Oxycodone is combined with RP-5063.Investigational
RucaparibThe metabolism of Oxycodone can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Oxycodone.Approved
SafinamideSafinamide may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational
SafrazineSafrazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Withdrawn
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Oxycodone.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Oxycodone is combined with Saredutant.Investigational
SarilumabThe therapeutic efficacy of Oxycodone can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxycodone.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Oxycodone.Approved
SerotoninThe risk or severity of adverse effects can be increased when Oxycodone is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Oxycodone.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sevoflurane.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SiltuximabThe serum concentration of Oxycodone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Oxycodone can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sisomicin.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Oxycodone.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Oxycodone.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Oxycodone.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Oxycodone.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Oxycodone.Approved
SpiradolineThe therapeutic efficacy of Spiradoline can be decreased when used in combination with Oxycodone.Investigational
SpironolactoneThe therapeutic efficacy of Spironolactone can be decreased when used in combination with Oxycodone.Approved
StiripentolThe serum concentration of Oxycodone can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxycodone.Approved
SufentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sufentanil.Approved, Investigational
SulconazoleThe metabolism of Oxycodone can be decreased when combined with Sulconazole.Approved
SulpirideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Oxycodone.Approved, Investigational
SuvorexantOxycodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Oxycodone is combined with Talopram.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Oxycodone is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Oxycodone.Approved, Withdrawn
TelithromycinThe risk or severity of adverse effects can be increased when Telithromycin is combined with Oxycodone.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxycodone.Approved, Investigational
TerbinafineThe metabolism of Oxycodone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe risk or severity of adverse effects can be increased when Terfenadine is combined with Oxycodone.Approved, Withdrawn
TetracyclineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrodotoxin.Investigational
ThalidomideOxycodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe therapeutic efficacy of Theobromine can be decreased when used in combination with Oxycodone.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of hypotension and central nervous system depression can be increased when Thiazinam is combined with Oxycodone.Experimental
ThiethylperazineThe risk or severity of hypotension and central nervous system depression can be increased when Thiethylperazine is combined with Oxycodone.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of hypotension and central nervous system depression can be increased when Thioproperazine is combined with Oxycodone.Approved
ThioridazineThe risk or severity of hypotension and central nervous system depression can be increased when Thioridazine is combined with Oxycodone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiothixene.Approved
ThonzylamineThe risk or severity of adverse effects can be increased when Thonzylamine is combined with Oxycodone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiagabine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Oxycodone can be decreased when combined with Ticagrelor.Approved
TicrynafenThe therapeutic efficacy of Ticrynafen can be decreased when used in combination with Oxycodone.Withdrawn
Tiemonium iodideThe risk or severity of adverse effects can be increased when Tiemonium iodide is combined with Oxycodone.Experimental
TigecyclineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tilidine.Experimental
TimepidiumThe risk or severity of adverse effects can be increased when Timepidium is combined with Oxycodone.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Oxycodone.Approved
TipranavirThe risk or severity of adverse effects can be increased when Tipranavir is combined with Oxycodone.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Oxycodone can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tofisopam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tolperisone.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxycodone.Approved, Investigational
TolvaptanThe therapeutic efficacy of Tolvaptan can be decreased when used in combination with Oxycodone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Topiramate.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Oxycodone.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxycodone.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tramiprosate.Investigational
TranylcypromineTranylcypromine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxycodone.Approved, Investigational
TriamtereneThe therapeutic efficacy of Triamterene can be decreased when used in combination with Oxycodone.Approved
TriazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triazolam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxycodone.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triclofos.Withdrawn
TridihexethylThe risk or severity of adverse effects can be increased when Tridihexethyl is combined with Oxycodone.Withdrawn
TrifluoperazineThe risk or severity of hypotension and central nervous system depression can be increased when Trifluoperazine is combined with Oxycodone.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of hypotension and central nervous system depression can be increased when Triflupromazine is combined with Oxycodone.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxycodone.Approved
TrimebutineThe risk or severity of adverse effects can be increased when Trimebutine is combined with Oxycodone.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trimethadione.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Oxycodone.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Oxycodone.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triprolidine.Approved
TroleandomycinThe risk or severity of adverse effects can be increased when Troleandomycin is combined with Oxycodone.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Oxycodone.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxycodone.Approved, Investigational
TropisetronThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tropisetron.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Oxycodone.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tubocurarine.Approved
UlaritideThe therapeutic efficacy of Ularitide can be decreased when used in combination with Oxycodone.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Oxycodone.Approved
UrapidilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Oxycodone is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Valnoctamide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Oxycodone is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vecuronium.Approved
VemurafenibThe serum concentration of Oxycodone can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Oxycodone.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Oxycodone.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vinylbital.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vortioxetine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Oxycodone is combined with Wortmannin.Experimental
XipamideThe therapeutic efficacy of Xipamide can be decreased when used in combination with Oxycodone.Experimental
XP19986The risk or severity of adverse effects can be increased when Oxycodone is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Oxycodone is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxycodone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Oxycodone.Approved, Investigational
ZolpidemOxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.

References

Synthesis Reference

Bao-Shan Huang, Yansong Lu, Ben-Yi Ji, Aris P Christodoulou, "Preparation of oxycodone from codeine." U.S. Patent US6008355, issued March, 1990.

US6008355
General References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433]
External Links
Human Metabolome Database
HMDB0014640
KEGG Drug
D05312
KEGG Compound
C08018
PubChem Compound
5284603
PubChem Substance
46508908
ChemSpider
4447649
BindingDB
50370595
ChEBI
7852
ChEMBL
CHEMBL656
Therapeutic Targets Database
DAP000283
PharmGKB
PA450741
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Oxycodone
ATC Codes
N02AA55 — Oxycodone, combinationsN02AA05 — Oxycodone
AHFS Codes
  • 28:08.08 — Opiate Agonists
FDA label
Download (689 KB)
MSDS
Download (50.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingBasic SciencePrescription Drug Abuse (Not Dependent)1
0RecruitingTreatmentLocally Advanced Head and Neck Cancer1
0RecruitingTreatmentUrologic Diseases1
1CompletedNot AvailableHealthy Volunteers15
1CompletedNot AvailableOpioid Analgesia1
1CompletedNot AvailableOsteoarthritis Thumbs1
1CompletedNot AvailablePain1
1CompletedBasic ScienceAnalgesia / Narcotic Abuse / Opioid-Related Disorders / Pain, Acute / Pain, Chronic1
1CompletedBasic ScienceHealthy Volunteers11
1CompletedBasic ScienceManagement of Moderate to Severe Pain1
1CompletedBasic ScienceOpioid Users1
1CompletedBasic SciencePain2
1CompletedOtherOpioid Abuse Nondependent1
1CompletedOtherPain, Chronic3
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentPain2
1RecruitingOtherPain, Chronic1
1RecruitingTreatmentColorectal Cancers1
1, 2CompletedTreatmentPain, Fracture, Sprain1
1, 2Not Yet RecruitingTreatmentAdenotonsillectomy / Opioids Use / Post-operative Analgesia1
2CompletedBasic ScienceOpioid-Related Disorders / Substance-Related Disorders1
2CompletedSupportive CareNutrition Disorders / Quality of Life1
2CompletedSupportive CarePain1
2CompletedTreatmentCancers / Occasional Constipation / Pain1
2CompletedTreatmentCancers / Pain1
2CompletedTreatmentDental Pain1
2CompletedTreatmentHeroin Dependence / Opioid-Related Disorders / Substance-Related Disorders1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)2
2CompletedTreatmentOpioid Abuse1
2CompletedTreatmentOpioid-Related Disorders1
2CompletedTreatmentPain, Acute1
2CompletedTreatmentPostoperative pain3
2Not Yet RecruitingBasic ScienceOpioid Abuse / Opioid-use Disorder1
2Not Yet RecruitingSupportive CareCarpal Tunnel Syndrome (CTS) / Cystic tumour of the ganglia / De Quervain's Disease / Dupuytren's Contracture / Trigger Digit1
2Not Yet RecruitingTreatmentGeneral Surgery1
2Not Yet RecruitingTreatmentOpioid-Related Disorders / Opioids Use / Rib Fractures1
2RecruitingPreventionPain, Neuropathic1
2RecruitingTreatmentOpioid-use Disorder1
2RecruitingTreatmentPain Management1
2RecruitingTreatmentTonsillectomy1
2RecruitingTreatmentPainful musculoskeletal conditions1
2TerminatedTreatmentOsteoarthritis (OA)1
2TerminatedTreatmentToothache1
2, 3CompletedTreatmentMalignant Pain / Non-malignant Pain1
2, 3RecruitingTreatmentChronic Rhinosinusitis (Diagnosis)1
3Active Not RecruitingTreatmentBrachial Plexus Block / Postoperative pain1
3Active Not RecruitingTreatmentGynecologic Cancers / Malignant Neoplasms of Female Genital Organs1
3CompletedNot AvailableSubjects With Moderate to Severe, Chronic Nonmalignant Pain1
3CompletedNot AvailableWithdrawal Symptoms1
3CompletedBasic ScienceLow Back Pain (LBP)1
3CompletedSupportive CareAnalgesia After ED Discharge for Extremity Injuries1
3CompletedSupportive CareChronic Noncancer Pain1
3CompletedSupportive CarePain1
3CompletedTreatmentAnalgesia / Low Back Pain (LBP) / Pain, Chronic1
3CompletedTreatmentArthralgia / Bunions / Hallux Valgus / Pain1
3CompletedTreatmentArthritis / Joint Diseases / Osteoarthritis (OA)1
3CompletedTreatmentBack Pain1
3CompletedTreatmentBack Pain / Back Pain With Radiation / Low Back Pain (LBP) / Pain1
3CompletedTreatmentCancers1
3CompletedTreatmentCancers / Pain1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Lower Back Pain / Osteoarthritis, Hip / Pain1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Pain1
3CompletedTreatmentLow Back Pain (LBP)2
3CompletedTreatmentModerate to Severe Postoperative Pain1
3CompletedTreatmentOpioids Use / Pain, Chronic1
3CompletedTreatmentOther Acute Postoperative Pain1
3CompletedTreatmentPain6
3CompletedTreatmentPain, Chronic1
3CompletedTreatmentPostoperative pain5
3CompletedTreatmentPostoperative pain / Prophylaxis against postoperative nausea and vomiting1
3CompletedTreatmentPruritus1
3CompletedTreatmentRenal Stones1
3Not Yet RecruitingTreatmentPain, Chronic1
3RecruitingSupportive CareBreast - Female1
3RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3RecruitingTreatmentAbortion in First Trimester1
3RecruitingTreatmentBack Pain / Cervical Pain1
3RecruitingTreatmentJoint Diseases1
3RecruitingTreatmentOpioids Use / Shoulder Pain1
3TerminatedTreatmentArthroplasty1
3TerminatedTreatmentOsteoarthritis (OA)1
3TerminatedTreatmentSevere Caner Pain1
3Unknown StatusSupportive CareCancers / Pain1
3Unknown StatusTreatmentBreakthrough Cancer Pain1
4Active Not RecruitingTreatmentCritical Illness1
4Active Not RecruitingTreatmentDrug Abuse / Narcotic Abuse / Opiate Addiction / Opioid-Related Disorders1
4Active Not RecruitingTreatmentPostoperative pain1
4CompletedNot AvailablePain1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceHealthy, no Evidence of Disease1
4CompletedBasic ScienceSubstance-Related Disorders1
4CompletedDiagnosticPain1
4CompletedSupportive CareCancers1
4CompletedSupportive CareEffects of 2 Mu-opiates on Gastrointestinal Transit1
4CompletedSupportive CarePain, Chronic1
4CompletedSupportive CarePain / Unspecified Adult Solid Tumor, Protocol Specific1
4CompletedSupportive CareSpinal Disorders / Spinal Disorders Related Pain1
4CompletedTreatmentAcute Low Back Pain1
4CompletedTreatmentArthroplasty, Replacement, Hip1
4CompletedTreatmentBack Pain / Low Back Pain (LBP) / Pain, Neuropathic1
4CompletedTreatmentBack Pain / Osteoarthritis (OA)1
4CompletedTreatmentBenign muscle neoplasm / Hysterectomy / Opioids / Postoperative pain1
4CompletedTreatmentCancers2
4CompletedTreatmentCancers / Pain, Cancer1
4CompletedTreatmentChronic Low Back Pain (CLBP) / Depression / Feeling Anxious / Intervertebral Disc Degeneration1
4CompletedTreatmentDisorder of Knee1
4CompletedTreatmentFlank Pain / Urinary Bladder, Overactive1
4CompletedTreatmentFracture Bone1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHeart; Dysfunction Postoperative, Cardiac Surgery1
4CompletedTreatmentImpaired Renal Function / Myocardial Infarction / Postoperative pain1
4CompletedTreatmentMAB / Pain1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentNausea1
4CompletedTreatmentOccasional Constipation1
4CompletedTreatmentOocyte Retrieval / Postoperative pain1
4CompletedTreatmentOpioid Related Disorders / Postoperative pain1
4CompletedTreatmentLumbar epidural anesthesia / Oral Oxycodone With/Without Naloxone / Postoperative Pain Management / Radical Cystectomy / Return of the Bowel Function1
4CompletedTreatmentOsteoarthritis (OA) / Pain, Chronic1
4CompletedTreatmentPain2
4CompletedTreatmentPain, Acute1
4CompletedTreatmentPain, Cancer1
4CompletedTreatmentPost Operative Pain2
4CompletedTreatmentPostcraniotomy Pain1
4CompletedTreatmentPostoperative pain3
4CompletedTreatmentUnilateral Knee Arthroplasty1
4Not Yet RecruitingTreatmentDistal Radius Fractures / Metacarpal Fractures / Pain Management1
4Not Yet RecruitingTreatmentInguinal Hernias / Postoperative pain1
4Not Yet RecruitingTreatmentOxycodone / Pharmacogenomics / Pharmacokinetics1
4Not Yet RecruitingTreatmentPain2
4Not Yet RecruitingTreatmentPostoperative pain2
4Not Yet RecruitingTreatmentPostoperative pain / Renal Stones1
4RecruitingBasic ScienceChronic Kidney Disease (CKD)1
4RecruitingOtherPediatric Surgical Patient1
4RecruitingSupportive CareDeglutition / Opioids Use / Pain, Chronic1
4RecruitingSupportive CareImpaired Renal Function / Pain / Terminal Illness1
4RecruitingSupportive CareScoliosis / Spondylolisthesis1
4RecruitingTreatmentAbortion Second Trimester1
4RecruitingTreatmentAnalgesics, Antipyretics, and Antirheumatics Causing Adverse Effects in Therapeutic Use / Opioids Use / Pain Uterus / Pain, Acute / Postoperative pain / Visceral Pain1
4RecruitingTreatmentBody Weight Changes / Postoperative Hemorrhages / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
4RecruitingTreatmentDiseases of Mitral Valve / Postoperative pain2
4RecruitingTreatmentHip Arthroscopy1
4RecruitingTreatmentLabour Pain1
4RecruitingTreatmentOccasional Constipation / Postoperative pain1
4RecruitingTreatmentOral Sedation and Cervical Dilator Pain1
4RecruitingTreatmentPain3
4RecruitingTreatmentPain Management1
4RecruitingTreatmentPain, Acute1
4RecruitingTreatmentPostoperative pain2
4RecruitingTreatmentSleep Apnea Syndrome1
4SuspendedTreatmentPain, Chronic1
4TerminatedNot AvailablePeripheral Neuropathy1
4TerminatedTreatmentAnesthesia Recovery Period / Postoperative pain1
4TerminatedTreatmentDisseminated Sclerosis / Pain, Chronic / Pain, Neuropathic1
4TerminatedTreatmentPain, Chronic1
4Unknown StatusNot AvailableOpioid Induced Constipation (OIC) / Postoperative pain1
4Unknown StatusTreatmentElective Laproscopic Bilateral Inguinal Hernia / Elective Laproscopic Cholecystectomy1
4Unknown StatusTreatmentLow Back Pain (LBP)1
4Unknown StatusTreatmentPost Operative Pain1
4WithdrawnTreatmentPain, Chronic1
4WithdrawnTreatmentPost Operative Pain Control1
Not AvailableActive Not RecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Fibrosis, Liver1
Not AvailableActive Not RecruitingSupportive CareHead and Neck Squamous Cell Carcinoma (HNSCC) / Pain / Vesicular Stomatitis1
Not AvailableCompletedNot AvailableBreakthrough Cancer Pain / Pain, Cancer / Pain, Neuropathic / Tumors1
Not AvailableCompletedNot AvailablePain1
Not AvailableCompletedNot AvailableSevere Pain1
Not AvailableCompletedNot AvailableSevere, Chronic Pain1
Not AvailableCompletedNot AvailableSubstance Abuse Detection1
Not AvailableCompletedBasic ScienceNarcotic Abuse1
Not AvailableCompletedPreventionCoughing Responses at Tracheal Extubation1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedTreatmentDrug Interactions1
Not AvailableCompletedTreatmentElbow Fractures1
Not AvailableCompletedTreatmentHip Fracture Surgery / Post Operative Pain Control1
Not AvailableCompletedTreatmentLabour Pain1
Not AvailableNot Yet RecruitingNot AvailableOxycontin1
Not AvailableNot Yet RecruitingTreatmentHerpes Zoster / Post-Herpetic Neuralgia (PHN)1
Not AvailableNot Yet RecruitingTreatmentPeripheral Arterial Disease (PAD)1
Not AvailableRecruitingNot AvailableMultimodal Analgesia / Nonsteroidal Anti-inflammatory Drugs1
Not AvailableRecruitingSupportive CareStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 / Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v81
Not AvailableRecruitingTreatmentChronic Pain, Postoperative / Postoperative pain1
Not AvailableRecruitingTreatmentGeneral Surgery / Pain / Rib Fractures / Traumas1
Not AvailableRecruitingTreatmentHip Pain Chronic1
Not AvailableSuspendedTreatmentLaceration / Pain1
Not AvailableTerminatedNot AvailableOsteoarthritis (OA)1
Not AvailableTerminatedSupportive CareBrain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Pain / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableTerminatedTreatmentAnaesthesia therapy1
Not AvailableUnknown StatusNot AvailableAnalgesic Response1
Not AvailableUnknown StatusTreatmentFlail Chest / General Surgery / Rib Fractures / Traumas1
Not AvailableWithdrawnSupportive CareLow Back Pain (LBP)1

Pharmacoeconomics

Manufacturers
  • Mallinckrodt inc
  • Purdue pharma lp
  • Roxane laboratories inc
  • Actavis totowa llc
  • Avanthi inc
  • Corepharma llc
  • Kv pharmaceutical co
  • Sun pharmaceutical industries inc
  • Tyco healthcare mallinckrodt
  • Vintage pharmaceuticals inc
  • Xanodyne pharmaceuticals inc
  • Endo Pharmaceuticals
Packagers
  • 4uOrtho LLC
  • Actavis Group
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Apotheca Inc.
  • Athlon Pharmaceuticals Inc.
  • Atley Pharmaceuticals
  • Barr Pharmaceuticals
  • Blenheim Pharmacal
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • Chattem Chemicals Inc.
  • Cody Laboratories Inc.
  • Core Pharmaceuticals
  • Corepharma LLC
  • D.M. Graham Laboratories Inc.
  • DAVA Pharmaceuticals
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dorx LLC
  • DSM Corp.
  • Endo Pharmaceuticals Inc.
  • Endogen
  • Ethex Corp.
  • Forest Pharmaceuticals
  • Glenmark Generics Ltd.
  • Global Pharmaceuticals
  • Impax Laboratories Inc.
  • Ivax Pharmaceuticals
  • Janssen-Ortho Inc.
  • KV Pharmaceutical Co.
  • KVK-Tech Inc.
  • Lake Erie Medical and Surgical Supply
  • Lannett Co. Inc.
  • Lehigh Valley Technologies Inc.
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Mckesson Corp.
  • Metrics Inc.
  • Midlothian Labs
  • Mikart Inc.
  • Mylan
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Ortho-McNeil-Janssen Pharmaceuticals Inc.
  • P F Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Purdue Pharma LP
  • Qualitest
  • Quality Care
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Rhodes Pharmaceutical LP
  • Roxane Labs
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • Superior Pharmeceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Ther-Rx Corp.
  • Victory Pharma
  • Vindex Pharmaceuticals Inc.
  • Vintage Pharmaceuticals Inc.
  • Vistapharm Inc.
  • Watson Pharmaceuticals
  • WraSer Pharmaceuticals
  • Xanodyne Pharmaceuticals Inc.
Dosage forms
FormRouteStrength
Tablet, extended releaseOral5 mg
Tablet, extended releaseOral10.0 mg
Tablet, extended releaseOral20.0 mg
Tablet, extended releaseOral40 mg
Tablet, extended releaseOral5.0 mg
Tablet, extended releaseOral80.0 mg
TabletOral7.5 mg/1
Tablet, multilayer, extended releaseOral20 mg
Capsule, gelatin coatedOral
CapsuleOral5 mg/1
SolutionOral100 mg/5mL
SolutionOral20 mg/mL
SolutionOral5 mg/5mL
Solution, concentrateOral20 mg/mL
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral5 mg/1
CapsuleOral
SolutionOral
Tablet, film coatedOral
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral20 mg/1
Tablet, extended releaseOral40 mg/1
Tablet, extended releaseOral80 mg/1
TabletOral80 mg/1
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral15 mg/1
Tablet, film coated, extended releaseOral20 mg/1
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral40 mg/1
Tablet, film coated, extended releaseOral60 mg/1
Tablet, film coated, extended releaseOral80 mg/1
Tablet, extended releaseOral15 mg
Tablet, extended releaseOral30 mg
Tablet, extended releaseOral60 mg
Tablet, extended releaseOral10 mg
Tablet, extended releaseOral20 mg
Tablet, extended releaseOral80 mg
TabletOral
Tablet, coatedOral15 mg/1
Tablet, coatedOral30 mg/1
Tablet, coatedOral5 mg/1
TabletOral20 mg
SuppositoryRectal10 mg
TabletOral10 mg
SuppositoryRectal20 mg
TabletOral5 mg
Tablet, extended releaseOral
Capsule, extended releaseOral
Tablet, coatedOral
Capsule, extended releaseOral13.5 mg/1
Capsule, extended releaseOral18 mg/1
Capsule, extended releaseOral27 mg/1
Capsule, extended releaseOral36 mg/1
Capsule, extended releaseOral9 mg/1
Prices
Unit descriptionCostUnit
Oxycodone hcl powder53.64USD g
Roxicodone 5 mg/5ml Solution 500ml Bottle53.0USD bottle
Roxicodone 20 mg/ml Concentrate 30ml Bottle46.99USD bottle
OxyCODONE HCl 20 mg/ml Concentrate 30ml Bottle33.99USD bottle
Oxycontin 60 mg tablet17.08USD tablet
OxyCONTIN 80 mg 12 Hour tablet14.36USD tablet
Oxycontin 20 mg tablet11.87USD tablet
Oxycontin 80 mg tablet11.53USD tablet
OxyCONTIN 60 mg 12 Hour tablet10.57USD tablet
Oxycontin 40 mg tablet9.45USD tablet
OxyCODONE HCl 80 mg 12 Hour tablet8.33USD tablet
OxyCONTIN 40 mg 12 Hour tablet7.68USD tablet
Oxycontin 10 mg tablet6.89USD tablet
Oxycontin 30 mg tablet6.59USD tablet
OxyCONTIN 30 mg 12 Hour tablet5.8USD tablet
Roxicodone 30 mg tablet5.19USD tablet
Oxycontin 80 mg Sustained-Release Tablet4.69USD tablet
OxyCODONE HCl 40 mg 12 Hour tablet4.38USD tablet
OxyCONTIN 20 mg 12 Hour tablet4.27USD tablet
Oxycontin 60 mg Sustained-Release Tablet3.55USD tablet
Oxycontin 15 mg tablet3.22USD tablet
Supeudol 20 mg Suppository2.95USD suppository
Roxicodone 15 mg tablet2.83USD tablet
Oxycodone hcl 10 mg tablet2.82USD tablet
Endocet 10-650 mg tablet2.7USD tablet
Endocet 7.5-325 mg tablet2.54USD tablet
Oxycontin 40 mg Sustained-Release Tablet2.54USD tablet
OxyCONTIN 10 mg 12 Hour tablet2.53USD tablet
Supeudol 10 mg Suppository2.33USD suppository
Roxicodone intensol 20 mg/ml2.3USD ml
Endocet 7.5-500 mg tablet2.22USD tablet
Oxycodone-apap 2.5-325 mg tablet2.05USD tablet
Percodan 4.5-0.38-325 mg tablet1.98USD tablet
Oxycontin 30 mg Sustained-Release Tablet1.96USD tablet
Endocet 10-325 mg tablet1.87USD tablet
Endocet 5-325 tablet1.82USD tablet
Percodan tablet1.62USD tablet
Oxycontin 20 mg Sustained-Release Tablet1.46USD tablet
Dazidox 20 mg tablet1.44USD tablet
Oxycodone hcl 30 mg tablet1.41USD tablet
Oxycontin 15 mg Sustained-Release Tablet1.19USD tablet
Endodan 4.83-325 mg tablet1.18USD tablet
Oxycodone hcl 20 mg tablet1.1USD tablet
Oxycontin 10 mg Sustained-Release Tablet0.98USD tablet
Oxycodone hcl 15 mg tablet0.9USD tablet
Oxycodone hcl 5 mg tablet0.81USD tablet
Dazidox 10 mg tablet0.75USD tablet
Oxy-Ir 20 mg Tablet0.74USD tablet
OxyCODONE HCl 5 mg capsule0.71USD capsule
Oxycontin 5 mg Sustained-Release Tablet0.7USD tablet
Endocet 5-325 mg tablet0.6USD tablet
Roxicodone 5 mg tablet0.56USD tablet
Oxyir 5 mg capsule0.52USD capsule
Oxy-Ir 10 mg Tablet0.43USD tablet
Pms-Oxycodone 20 mg Tablet0.42USD tablet
Supeudol 20 mg Tablet0.42USD tablet
Oxycodone 5 mg tablet0.36USD tablet
Pms-Oxycodone 10 mg Tablet0.24USD tablet
Supeudol 10 mg Tablet0.24USD tablet
Pms-Oxycodone 5 mg Tablet0.14USD tablet
Supeudol 5 mg Tablet0.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5508042No1993-04-162013-04-16Us
CA2098738No1999-08-172012-11-25Canada
US9205082No2002-05-102022-05-10Us
US6488962No2000-06-202020-06-20Us
US8309060No2003-11-202023-11-20Us
US8808741No2007-08-242027-08-24Us
US9073933No2005-03-302025-03-30Us
US9060976No2002-08-062022-08-06Us
US6488963No1997-06-242017-06-24Us
US7674800No2005-03-302025-03-30Us
US7683072No2005-03-302025-03-30Us
US8337888No2002-08-062022-08-06Us
US7776314No2005-04-192025-04-19Us
US8894988No2007-08-242027-08-24Us
US7674799No2005-03-302025-03-30Us
US8114383No2004-10-102024-10-10Us
US8894987No2010-03-292030-03-29Us
US8685443No2005-07-032025-07-03Us
US7815934No2007-12-122027-12-12Us
US9168252No2002-05-102022-05-10Us
US9161937No2002-05-102022-05-10Us
US8969369No2002-05-102022-05-10Us
US9084729No2002-05-102022-05-10Us
US9283216No2002-05-102022-05-10Us
US9056051No2002-05-102022-05-10Us
US8846090No2003-04-042023-04-04Us
US6277384No1998-12-222018-12-22Us
US8822487No1998-12-222018-12-22Us
US8673355No1998-12-222018-12-22Us
US6696066No1998-12-222018-12-22Us
US8846091No2003-04-042023-04-04Us
US8372432No2009-03-112029-03-11Us
US8668929No2009-03-112029-03-11Us
US8377453No2009-11-192029-11-19Us
US7976870No2007-06-012027-06-01Us
US8741885No2012-05-162032-05-16Us
US8992975No2012-05-162032-05-16Us
US8597681No2010-12-212030-12-21Us
US8980319No2010-12-212030-12-21Us
US8394408No2009-03-112029-03-11Us
US9050335No2012-05-162032-05-16Us
US8658631No2012-05-162032-05-16Us
US7510726No2003-11-262023-11-26Us
US8409616No2003-11-262023-11-26Us
US7201920No2005-03-162025-03-16Us
US8637540No2003-11-262023-11-26Us
US7981439No2003-11-262023-11-26Us
US7955619No2008-08-122028-08-12Us
US9492389No2007-08-242027-08-24Us
US9522919No2005-03-302025-03-30Us
US9492392No2007-08-242027-08-24Us
US9492391No2007-08-242027-08-24Us
US9492393No2007-08-242027-08-24Us
US9345701No2002-05-102022-05-10Us
US9511066No2002-05-102022-05-10Us
US9555000No2003-04-042023-04-04Us
US9474750No1998-12-222018-12-22Us
US9283221No2002-05-102022-05-10Us
US9468636No2012-05-162032-05-16Us
US9492443No2004-05-262024-05-26Us
US9044398No2003-07-072023-07-07Us
US7771707No2005-03-242025-03-24Us
US9248195No2003-07-072023-07-07Us
US8557291No2005-03-212025-03-21Us
US8449909No2005-03-242025-03-24Us
US7399488No2005-03-242025-03-24Us
US9592200No2003-07-072023-07-07Us
US9682075No2010-12-102030-12-10Us
US8758813No2005-06-102025-06-10Us
US8840928No2003-07-072023-07-07Us
US9675610No2003-06-162023-06-16Us
US9737530No2016-09-022036-09-02Us
US9763933No2007-08-242027-08-24Us
US9770416No2007-08-242027-08-24Us
US9775808No2007-08-242027-08-24Us
US9763883No2003-07-072023-07-07Us
US9907793No2003-04-042023-04-04Us
US9968598No2016-09-022036-09-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)219 °CPhysProp
water solubility100 mg/mlNot Available
logP0.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.59 mg/mLALOGPS
logP1.04ALOGPS
logP1.03ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)8.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity84.04 m3·mol-1ChemAxon
Polarizability32.8 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.9885
Caco-2 permeable+0.7774
P-glycoprotein substrateSubstrate0.8996
P-glycoprotein inhibitor IInhibitor0.539
P-glycoprotein inhibitor IINon-inhibitor0.9122
Renal organic cation transporterNon-inhibitor0.5413
CYP450 2C9 substrateNon-substrate0.822
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7796
CYP450 1A2 substrateNon-inhibitor0.9327
CYP450 2C9 inhibitorNon-inhibitor0.9431
CYP450 2D6 inhibitorNon-inhibitor0.5131
CYP450 2C19 inhibitorNon-inhibitor0.882
CYP450 3A4 inhibitorNon-inhibitor0.8714
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9691
Ames testNon AMES toxic0.7337
CarcinogenicityNon-carcinogens0.9557
BiodegradationNot ready biodegradable0.9746
Rat acute toxicity3.0638 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9402
hERG inhibition (predictor II)Non-inhibitor0.9279
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-014i-6975000000-ecd49efa58246c903e23
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0009000000-d55749fa4d1f47ce2244
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kb-0095000000-83c78e9e15857145cc78
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0090000000-ad908ecfa38c7efce138
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0390000000-88d302b8770cb7121937
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03fu-0790000000-4af50b834ee854320001

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenanthrenes and derivatives
Sub Class
Not Available
Direct Parent
Phenanthrenes and derivatives
Alternative Parents
Isoquinolones and derivatives / Tetralins / Coumarans / Anisoles / Alkyl aryl ethers / Aralkylamines / Piperidines / Tertiary alcohols / Trialkylamines / 1,2-aminoalcohols
show 7 more
Substituents
Phenanthrene / Isoquinolone / Tetralin / Coumaran / Anisole / Alkyl aryl ether / Aralkylamine / Piperidine / Cyclic alcohol / Tertiary alcohol
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heteropentacyclic compound (CHEBI:7852)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433]
  3. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433]
  3. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT: Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain. 2007 Dec 5;132(3):289-300. Epub 2007 Apr 30. [PubMed:17467904]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
4. Kappa-type opioid receptor 2b
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
References
  1. Smith MT: Differences between and combinations of opioids re-visited. Curr Opin Anaesthesiol. 2008 Oct;21(5):596-601. doi: 10.1097/ACO.0b013e32830a4c4a. [PubMed:18784485]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...

Components:
References
  1. Leow KP, Wright AW, Cramond T, Smith MT: Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther Drug Monit. 1993 Oct;15(5):440-7. [PubMed:8249052]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:21